The cytokine and cell adhesion protein osteopontin (OPN) has been implicated in tumor progression in tumors of various origins including breast, prostate, lung, colon, and head and neck tumors (Coppola et al, 2004) . OPN protein levels in the tumors were highest in tumors of gastrointestinal, genitourinary, and gynecological origin, and lowest in tumors of the breast, skin, brain, and salivary gland. Whether OPN is expressed by the tumor cells, peritumoral inflammatory cells, or both, its expression correlated positively with tumor stage, dramatically so in colon adenocarcinomas. A partial explanation for this may be that OPN can stimulate angiogenesis, possibly by recruiting proangiogenic monocytes (Hirama et al, 2003; Leali et al, 2003) . Now in this issue of JID, Youwen Zhou, Gang Li, and colleagues working at the University of British Columbia, Canada, describe a microarray study of gene expression in developing metastatic human melanomas, revealing that OPN expression increased significantly when the melanomas acquired invasive, metastatic capabilities.
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OPN is a secreted phosphoprotein found in all body fluids and mineralized tissues (Sodek et al, 2000) . Because it is a ligand for several widely expressed integrins including avb1, 3, or 5, and a4, 8, or 9b1, and certain CD44 variants, it is capable of activating signal transduction pathways controlled by these receptors (Denhardt et al, 2001a) . OPN binds strongly to bone mineral, via both its multiple phosphoserine residues and its aspartic acid-rich domain, thereby supporting the attachment of bone cells to bone mineral via the above-mentioned receptors. Its role as a cytokine is less evident, but obviously important, particularly during the inflammatory response where its expression is increased and it attracts monocytes/macrophages to sites of injury and infection, regulates NFkB and iNOS expression, and alters the Th1/Th2 ratio (Denhardt et al, 2001a, b) .
A number of studies suggest that OPN signaling facilitates the survival of cells subjected to various stressful situations, hypoxia or growth factor-deprivation for example (Denhardt et al, 2003) . Importantly, OPN-deficient (knockout) mice are defective in bone remodeling and resistant to the progression of autoimmune disease (Denhardt et al, 2001a, b) . Both phenotypes may result from the ability of OPN to inhibit the apoptotic response of bone or immune cells that would otherwise die. Similarly, it is possible that OPN promotes metastasis by prolonging the survival of cancer cells. Consistent with such a model are the results reported by Ohyama et al (2004) that B16F10 melanoma cells injected into ablated bone marrow cavities formed 5fold fewer tumors in OPN-deficient mice than in control mice. It appears that the presence of exogenous host OPN facilitated the attachment, survival, and/or growth of the melanoma cells. Presumably, high-level expression of OPN by the tumor cells would serve a similar purpose.
Because OPN expression is increased by activation of Ras, protein kinase C, or PI3-K/Akt, it is not surprising to find elevated OPN levels in tumors where the signal transduction pathways involving these molecules are upregulated (Denhardt et al, 2001a (Denhardt et al, , b, 2003 , e.g., in the hypoxic, low-pH environment of tumors (Le et al, 2003) . That OPN actually stimulates tumor progression and metastasis has been documented in studies reporting that targeted downregulation (by anti-sense RNA or small inhibitory RNA (siRNA)) or upregulation (by direct transfection of an OPN-expressing construct) of OPN expression caused a decrease or increase, respectively, of the tumorigenic/metastatic efficiency (Denhardt et al, 2001a, b; Adwan et al, 2004; Rittling and Chambers, 2004) .
Studies on the hepatocyte growth factor/scatter factor (HGF/SCF)-Met receptor tyrosine kinase axis have shed light on a second mechanism by which OPN can stimulate metastasis. Tuck et al (2000) described experiments showing that OPN-induced migration of mammary epithelial cells involved activation of Met, possibly indirectly through avb3 rather than through HGF/SCF. Medico et al (2001) found that HGF not only stimulated OPN expression in mouse liver progenitor cells but also promoted cell adhesion to OPN via CD44, the hyaluronan receptor; they suggested that OPN was an autocrine mediator of HGF/SCF-induced invasive growth. Recio and Merlino (2003) described a feedback loop in which CD44v6, an OPN receptor, and Met were upregulated by HGF in melanoma cells, perhaps to compensate for depletion of the Met receptor resulting from HGF signaling. Ariztia et al (2003) , using a mouse liver epithelial line, showed that HGF-induced tumorigenesis and experimental metastasis formation were both attenuated by antisense OPN-mediated inhibition of OPN expression. They also showed that enhanced OPN expression alone did not confer tumorigenicity of metastatic ability on these cells. The mRNA encoding CD63, which encodes a melanomaassociated antigen (ME491) that belongs to the tetraspan family of receptors, was also upregulated by HGF. As HGF/ Abbreviations: HGF, hepatocyte growth factor; OPN, osteopontin xvi SCF-Met have been implicated in melanoma development (Li et al, 2001; Walker and Hayward, 2002) , it would appear that contributing to melanoma progression is a complicated positive feedback loop involving Met and OPN along with its integrin and CD44 receptors.
Melanocytes, from which melanomas originate, are normally restricted to the basal layer of the epidermis, in part because dermal collagen induces their apoptosis possibly because of their inability to adhere to native collagen Type I (Geissinger et al, 2002) . Therefore, as a first step, in melanoma progression, melanocytes must acquire the ability to invade and survive in the dermal layer, events in part regulated by basic fibroblast growth factor (bFGF) (Alanko et al, 1999) . Geissinger et al (2002) reported that OPN, which can be induced by bFGF (FGF2), inhibited apoptosis of melanocytes grown in dermal collagen by a process dependent upon OPN binding to the avb3 integrin. Petitclerc et al (1999) reported that avb3 was required for survival and growth of melanoma tumors in full-thickness human skin. Although the authors suggested that denatured proteolytically cleaved collagen was the ligand responsible, a role for OPN was not excluded. The ability of soluble OPN to bind to several receptors typically engaged by molecules constituting the extracellular matrix (ECM), and thereby mimicking ECM signaling, may be a unique feature of OPN (Denhardt et al, 2001b) .
Matrix metalloproteinases (MMP) and serine proteinases (e.g., urokinase-type plasminogen activator) are important weapons in the metastatic cell arsenal; they can degrade both cell adhesion molecules and ECM molecules, enabling tumor cells both to escape from a tumor and to invade adjacent tissues. OPN regulates MMP activities in various ways. It can bind to proMMP-9 and promote its activation (Fedarko et al, 2004) , and it can induce NFkB-mediated proMMP-2 and -9 activation through an IkBa/IKK signaling pathway (Rangaswami et al, 2004) . These proteinases have the potential to cleave cell adhesion molecules, thereby facilitating the release of tumor cells from the growing tumor. Autocrine HGF signaling was reported by Li et al (2001) to downregulate levels of the melanoma adhesion proteins Ecadherin and Desmoglein I, possibly in part by proteolysis, thereby enabling tumor cell dissemination. OPN can also increase uPA mRNA levels and urokinase activity in medium conditioned by breast cancer cells, enhancing their invasiveness (Tuck et al, 1999) . Thus in two quite different ways (inhibiting tumor cell apoptosis, stimulating tumor cell, or endothelial cell invasiveness) OPN accelerates tumor progression. Zhou et al (2005) report in their high-density DNA microarray analysis that among 14 (of 14,000) genes whose transcripts were highly (20-fold) overexpressed in metastatic melanoma nodules, OPN was the most abundant. OPN upregulation in metastatic nodules and melanoma cell lines was confirmed at the mRNA level by quantitative RT-PCR and also by western analysis of OPN protein levels in the melanoma lines, all of which were derived from metastatic melanomas and were highly metastatic. Suppression of OPN expression in one of these lines (KZ-28) by means of a siRNA reduced the cell number measured 2 days later, consistent with the possibility that OPN either stimulated proliferation or inhibited apoptosis of this cell line in culture.
Although not tested, results in other systems imply that the tumorigenicity and experimental metastatic efficiency of these cells will be reduced in comparison with the parent cells. This study thus adds skin cancer (melanomas) to the set of cancers (above) in which OPN expression not only increases as the tumors become progressively more malignant but also contributes actively in one or more ways to tumor invasion and metastasis (Furger et al, 2001; Weber, 2001) . Zhou et al (2005) suggest that OPN might serve as a therapeutic target for melanoma; however, the authors also note that in contrast to many other cancers, no correlation between OPN expression and metastasis or patient survival has been reported so far. DOI: 10.1111 DOI: 10. /j.0022-202X.2005 
